{"id":745502,"date":"2017-09-06T05:30:00","date_gmt":"2017-09-06T05:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology\/"},"modified":"2025-11-07T01:26:18","modified_gmt":"2025-11-07T06:26:18","slug":"merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology\/","title":{"rendered":"Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada, and<br \/>\n      Rigontec today announced that Merck will acquire Rigontec. Rigontec is a<br \/>\n      pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway,<br \/>\n      part of the innate immune system, as a novel and distinct approach in<br \/>\n      cancer immunotherapy to induce both immediate and long-term anti-tumor<br \/>\n      immunity. Rigontec\u2019s lead candidate, RGT100, is currently in Phase I<br \/>\n      development evaluating treatment in patients with various tumors.\u00a0Under<br \/>\n      the terms of the agreement, Merck, through a subsidiary, will make an<br \/>\n      upfront cash payment of \u20ac115 million to Rigontec\u2019s shareholders; based<br \/>\n      on the attainment of certain clinical, development, regulatory and<br \/>\n      commercial milestones, Merck may make additional contingent payments of<br \/>\n      up to \u20ac349 million. The transaction is subject to certain closing<br \/>\n      conditions.\n    <\/p>\n<p>\n      \u201cRigontec\u2019s immuno-oncology approach of engaging the innate immune<br \/>\n      system to safely eliminate cancer cells complements our strategy and our<br \/>\n      current pipeline,\u201d said Dr. Eric Rubin, vice president of early-stage<br \/>\n      development, clinical oncology,\u00a0Merck Research Laboratories. \u201cWe are<br \/>\n      eager to build upon Rigontec\u2019s science as we continue our efforts in<br \/>\n      bringing forward meaningful advances for patients with cancer.\u201d\n    <\/p>\n<p>\n      \u201cMerck is a true pioneer in the immuno-oncology space and we are<br \/>\n      thrilled that our technology will benefit from their experience and<br \/>\n      leadership position,\u201d said Christian Schetter, Ph.D., CEO of Rigontec.<br \/>\n      \u201cWe are confident that our programs will be in the best hands and that<br \/>\n      the team at Merck will continue the work we established with our<br \/>\n      scientific founders and brought into the clinic within three years since<br \/>\n      our foundation as a company.\u201d\n    <\/p>\n<p>\n      <b>About Rigontec<\/b>\n    <\/p>\n<p>\n      Rigontec is the leader in RIG-I targeting therapeutics. Utilizing the<br \/>\n      proprietary RIG-I agonist approach, the company harnesses one of the<br \/>\n      most essential pathways in the innate immune system to pioneer a novel<br \/>\n      immuno-oncology treatment approach. Rigontec\u2019s proprietary agonists<br \/>\n      specifically activate RIG-I, inducing both immediate and long-term<br \/>\n      anti-tumor immunity and have proven substantial local and systemic tumor<br \/>\n      regression in several relevant <i>in vivo<\/i> models. In addition to<br \/>\n      malignant diseases, proprietary RNA molecules can be developed for the<br \/>\n      treatment of infectious and inflammatory diseases.\n    <\/p>\n<p>\n      Rigontec was founded in 2014 as a spin-out of the University Bonn,<br \/>\n      Germany, and has to date raised close to \u20ac30 million from experienced<br \/>\n      life science investors including Boehringer Ingelheim Venture Fund,<br \/>\n      Forbion Capital Partners, High-Tech Gru\u0308nderfonds, MP Healthcare Venture<br \/>\n      Management, NRW.BANK, Sunstone Capital and Wellington Partners Life<br \/>\n      Sciences.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 550 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51671264&amp;newsitemid=20170906005092&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=b4f2a65c1cddbe326bd0492cf978975d\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51671264&amp;newsitemid=20170906005092&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=d1201c9f09457f52ec78c89efdcf8287\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n<span class=\"bwuline\"><br \/>\n      <\/span>and\u00a0connect with us on\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51671264&amp;newsitemid=20170906005092&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=cb6a686f1437bd5d5f319ecf6d39e503\" rel=\"nofollow\">Twitter<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51671264&amp;newsitemid=20170906005092&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=58bbf9a7e73d5e6f2a7494ac95b11522\" rel=\"nofollow\">Facebook<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51671264&amp;newsitemid=20170906005092&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=76c9b847770dafdf8b7a79a7a4093143\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51671264&amp;newsitemid=20170906005092&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=10f75d2f24e05a81b5c3041d418efdc7\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51671264&amp;newsitemid=20170906005092&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=75f0b59c93c673891fbc56ae07ad7d26\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51671264&amp;newsitemid=20170906005092&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=97748fb8ba64152c0380cca8da64ed6d\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170906005092r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Media:<br \/>Pamela Eisele, Merck<br \/>267-305-3558<br \/>or<br \/>Kim        Hamilton, Merck<br \/>908-740-1863<br \/>or<br \/>Dr. Stephanie May,        Rigontec<br \/>MacDougall Biomedical Communications<br \/>+49 175 5711562<br \/>or<br \/>Investors:<br \/>Teri        Loxam, Merck<br \/>908-740-1986<br \/>or<br \/>Amy Klug, Merck<br \/>908-740-1898<br \/>or<br \/>Dr.        Christian Schetter, Rigontec<br \/>+49 151 466 75 978     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Rigontec today announced that Merck will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity. Rigontec\u2019s lead candidate, RGT100, is currently in Phase I development evaluating treatment in patients with various tumors.\u00a0Under the terms of the agreement, Merck, through a subsidiary, will make an upfront cash payment of \u20ac115 million to Rigontec\u2019s shareholders; based on the attainment of certain clinical, development, regulatory and commercial milestones, Merck may make additional contingent payments of up to \u20ac349 million. The transaction is subject to certain closing conditions. \u201cRigontec\u2019s immuno-oncology approach of engaging the innate immune system to safely eliminate cancer cells complements our strategy and our<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745502","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Rigontec today announced that Merck will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity. Rigontec\u2019s lead candidate, RGT100, is currently in Phase I development evaluating treatment in patients with various tumors.\u00a0Under the terms of the agreement, Merck, through a subsidiary, will make an upfront cash payment of \u20ac115 million to Rigontec\u2019s shareholders; based on the attainment of certain clinical, development, regulatory and commercial milestones, Merck may make additional contingent payments of up to \u20ac349 million. The transaction is subject to certain closing conditions. \u201cRigontec\u2019s immuno-oncology approach of engaging the innate immune system to safely eliminate cancer cells complements our strategy and our\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology\\\/\",\"name\":\"Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-09-06T05:30:00+00:00\",\"dateModified\":\"2025-11-07T06:26:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology\/","og_locale":"en_US","og_type":"article","og_title":"Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Rigontec today announced that Merck will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity. Rigontec\u2019s lead candidate, RGT100, is currently in Phase I development evaluating treatment in patients with various tumors.\u00a0Under the terms of the agreement, Merck, through a subsidiary, will make an upfront cash payment of \u20ac115 million to Rigontec\u2019s shareholders; based on the attainment of certain clinical, development, regulatory and commercial milestones, Merck may make additional contingent payments of up to \u20ac349 million. The transaction is subject to certain closing conditions. \u201cRigontec\u2019s immuno-oncology approach of engaging the innate immune system to safely eliminate cancer cells complements our strategy and our","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:18+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology\/","name":"Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-09-06T05:30:00+00:00","dateModified":"2025-11-07T06:26:18+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-rigontec-rig-i-therapeutics-pioneer-advancing-leadership-in-immuno-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"a42b91ad-45dc-4555-9ab4-62014ef58d67","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745502\/revisions"}],"predecessor-version":[{"id":3674858,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745502\/revisions\/3674858"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745502"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}